BiotechTube

LY2624803

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Insomnia

Conditions

Insomnia

Trial Timeline

Nov 1, 2010 → Nov 1, 2010

NCT ID
NCT01257178

About LY2624803

LY2624803 is a phase 1 stage product being developed by Eli Lilly for Insomnia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01257178. Target conditions include Insomnia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01257178Phase 1Terminated
NCT01236105Phase 1Completed

Competing Products

20 competing products in Insomnia

See all competitors
ProductCompanyStageHype Score
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2IdorsiaPhase 2
47
Zolpidem (Myslee®) + placeboAstellas PharmaApproved
85
zolpidemAstellas PharmaApproved
85
Mirtazapine TabletsSun PharmaceuticalApproved
85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)EisaiApproved
85
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched PlaceboEisaiPhase 1
33
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mgEisaiPhase 1
33
E2006EisaiPhase 1
33
Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placeboEisaiPhase 3
77
LEM 5 mg + LEM 10 mgEisaiPhase 3
77
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mgEisaiPhase 2/3
65
lemborexant + PlaceboEisaiPhase 3
77
E2006 + PlaceboEisaiPhase 2
52
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexantEisaiPhase 1
33
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderlyEisaiPhase 3
77
Eszopiclone 3 mg + Eszopiclone 1 mgEisaiPhase 1
33
LY2624803Eli LillyPhase 1
33
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - TabletsEli LillyPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85